An Expert Report on Meningococcal Polysaccharide Serogroup Y Vaccine Component (DB13888): From Polysaccharide Antigen to Modern Conjugate Vaccines

I. Introduction: The Pathogen and the Antigen

1.1. Neisseria meningitidis and the Burden of Invasive Disease

Neisseria meningitidis, often referred to as the meningococcus, is a Gram-negative diplococcus bacterium and an obligate human pathogen.[1] It resides as a commensal organism in the nasopharyngeal mucosa of a significant portion of the healthy population, with carriage rates estimated at 8–25% in adults.[1] While typically harmless in this state, the bacterium can breach the mucosal barrier and invade the bloodstream, leading to Invasive Meningococcal Disease (IMD). IMD manifests primarily in two devastating forms: meningitis, an infection of the protective membranes surrounding the brain and spinal cord, and meningococcemia, a life-threatening bloodstream infection (sepsis).[1]

The clinical severity of IMD is profound. Even with the availability of advanced medical care and antimicrobial therapy, the disease progresses with alarming speed and carries a case-fatality rate of 10–15%.[3] Among those who survive, a substantial proportion—approximately 10 to 20 out of every 100—suffer from permanent and debilitating sequelae, which can include profound hearing loss, irreversible neurologic damage, kidney failure, or the loss of limbs due to vascular compromise and tissue necrosis.[4]

The epidemiology of meningococcal disease is dynamic and varies significantly by geographical region, patient age, and the specific causative serogroup.[4] The primary virulence factor of

N. meningitidis is its polysaccharide capsule, which protects the bacterium from host phagocytosis and forms the basis for its classification into at least 13 distinct serogroups.[1] Of these, six serogroups—A, B, C, W, X, and Y—are responsible for the vast majority of IMD cases worldwide.[8] Disease incidence peaks in specific age groups, most notably in infants under one year of age, whose immune systems are still developing, and again in adolescents and young adults aged 16 through 23, a period associated with social behaviors that facilitate transmission.[4]

The distribution of these serogroups is not static. A pivotal epidemiological shift occurred in the United States, where serogroup Y, once a minor cause of IMD, saw its prevalence increase dramatically. Data from multistate surveillance showed that the proportion of cases caused by serogroup Y rose from just 2% in the early 1990s to 37% by the early 2000s, establishing it as a leading cause of disease alongside serogroups B and C.[7] This trend fundamentally altered the public health landscape and created an urgent need for vaccines offering broader protection beyond the historically dominant serogroups A and C. This epidemiological pressure was a direct driver for the development and widespread implementation of quadrivalent vaccines containing the serogroup Y antigen, marking a crucial evolution in the strategy to prevent this devastating disease.

1.2. The Serogroup Y Capsular Polysaccharide (DB13888): A Biochemical and Structural Profile

The key antigenic component used to elicit immunity against Neisseria meningitidis serogroup Y is its purified capsular polysaccharide, cataloged in DrugBank under the accession number DB13888.[2] This biotech component is also identified by several synonyms, including meningococcal polysaccharide antigen group Y and

Neisseria meningitidis group Y capsular polysaccharide antigen.[2] It is extracted and purified from cultures of

N. meningitidis serogroup Y and serves as the active immunizing agent in vaccines.[2]

From a biochemical perspective, the serogroup Y polysaccharide is a high molecular weight polymer. Its structure consists of an alternating sequence of two sugar residues: D-glucose and N-acetylneuraminic acid (also known as sialic acid).[13] These residues are joined by specific glycosidic linkages to form a repeating disaccharide unit: →6)-α-D-glucopyranosyl-(1→4)-α-D-N-acetylneuraminic acid-(2→.[13] This polysaccharide may also be partially O-acetylated, a modification that can influence its immunogenicity.[13] The molecular size and integrity of the polysaccharide chain are considered critical physicochemical parameters that correlate with the vaccine's potency and efficacy.[11]

The structure of the serogroup Y polysaccharide is remarkably similar to that of the serogroup W polysaccharide. The serogroup W polymer is also composed of a repeating sialic acid-hexose disaccharide, differing only in the identity of the hexose sugar, which is D-galactose instead of D-glucose.[14] While this chemical similarity might suggest that the two polysaccharides would adopt nearly identical three-dimensional shapes and potentially elicit cross-protective antibodies, advanced molecular modeling studies have revealed subtle yet significant conformational differences. Molecular dynamics simulations indicate that the serogroup Y polysaccharide adopts a single, dominant, and relatively rigid elongated helical structure.[14] In contrast, the serogroup W polysaccharide exhibits greater conformational flexibility, existing as a family of different spatial arrangements.[14]

This distinction in three-dimensional topology is not merely a minor biochemical detail; it has profound immunological implications. The specific shape, or conformation, of an antigen dictates the epitopes—the precise molecular patterns—that are presented to the host immune system. The more constrained and defined structure of the serogroup Y polysaccharide likely presents a consistent set of epitopes, leading to a highly specific antibody response. The flexibility of the serogroup W polysaccharide may present a wider array of epitopes, potentially leading to a different quality of immune response. These conformational differences provide a molecular basis for the observed variations in immunological cross-protection between the two serogroups and underscore why, despite their chemical similarity, they must be treated as distinct antigens in the formulation of multivalent vaccines.[14]

II. Immunological Principles: The Critical Shift from Polysaccharide to Conjugate Vaccines

The history of meningococcal vaccination is defined by a fundamental technological and immunological leap: the transition from plain polysaccharide vaccines to protein-polysaccharide conjugate vaccines. This evolution was driven by the need to overcome the inherent limitations of the immune response to polysaccharide antigens, particularly in the most vulnerable populations. Understanding the mechanisms behind these two vaccine types is essential to appreciating the superior efficacy and public health impact of modern meningococcal vaccines incorporating the serogroup Y antigen.

2.1. The Plain Polysaccharide Vaccine (PSV) Paradigm: T-Cell Independent Immunity

The first generation of meningococcal vaccines, including the quadrivalent formulation containing the serogroup Y antigen, were composed of purified capsular polysaccharides.[7] These molecules, by their nature, act as T-cell independent (TI) antigens.[16] The immune response they elicit follows a distinct and limited pathway. TI antigens are capable of directly stimulating mature B-lymphocytes, often by cross-linking multiple B-cell receptors on the cell surface, which triggers their differentiation into antibody-producing plasma cells.[16]

However, this activation occurs without the critical involvement of T-helper cells. The absence of this T-cell help has several significant immunological consequences that translate directly into clinical limitations [16]:

1. Predominantly IgM Response: The antibody response is largely restricted to the IgM isotype. There is minimal to no class switching to produce long-lived, high-affinity IgG antibodies, which are generally more effective in providing sustained protection.[16]
2. Lack of Immunological Memory: The TI pathway does not lead to the generation of a robust population of memory B-cells. Without immunological memory, the body cannot mount a rapid and heightened (anamnestic) response upon subsequent exposure to the pathogen or a booster dose of the vaccine.[16]
3. Poor Immunogenicity in Infants: The TI immune response is age-dependent and is particularly weak in infants and children under two years of age.[4] This is a critical deficiency, as this age group is at a very high risk for invasive meningococcal disease.
4. Short Duration of Protection: Due to the lack of memory cells and the transient nature of the IgM response, the protection afforded by polysaccharide vaccines wanes relatively quickly, typically within three to five years.[18]
5. Induction of Hyporesponsiveness: Paradoxically, repeated immunization with polysaccharide vaccines does not produce a booster effect. Instead, it can lead to a state of immunological hyporesponsiveness, or tolerance, where the immune system's ability to respond to subsequent doses of the vaccine is impaired.[16] This phenomenon represents a significant clinical liability for individuals requiring long-term protection, as repeated vaccination could become counterproductive.

2.2. The Advent of Conjugation Technology: T-Cell Dependent Immunity

To overcome the limitations of PSVs, scientists developed conjugation technology. This process involves the covalent linkage of the polysaccharide antigen (which is recognized by B-cells) to a large protein carrier, such as diphtheria toxoid, a non-toxic mutant of diphtheria toxin known as CRM197, or tetanus toxoid.[16] This molecular engineering fundamentally transforms the polysaccharide from a T-cell independent antigen into a T-cell dependent (TD) antigen, thereby recruiting the full power of the adaptive immune system.[16]

The TD immune response mechanism is far more sophisticated and robust. A B-cell recognizes and binds to the polysaccharide portion of the conjugate vaccine. The entire conjugate molecule is then internalized by the B-cell. Inside the cell, the protein carrier is broken down into small peptides, which are then presented on the B-cell's surface via Major Histocompatibility Complex (MHC) class II molecules. A T-helper cell that recognizes this specific peptide-MHC complex then provides co-stimulatory signals to the B-cell.[16] This crucial B-cell/T-cell collaboration unleashes a cascade of events that confers major immunological advantages over the TI response [16]:

1. Enhanced Immunogenicity in All Ages: Conjugate vaccines are highly immunogenic even in infants as young as two months old, effectively closing the gap in protection for this vulnerable population.[4]
2. Antibody Isotype Switching and Affinity Maturation: The T-cell help drives B-cells to undergo isotype switching, leading to the production of high-affinity IgG antibodies. These antibodies are more potent and have a longer half-life than IgM, providing more effective and durable protection.[16]
3. Induction of Immunological Memory: A key outcome of the TD response is the generation of long-lived memory B-cells and memory T-cells. This immunological memory primes the body for a rapid and powerful anamnestic response upon future encounters with the meningococcus, forming the basis for long-term immunity and effective booster responses.[16]

2.3. Impact on Nasopharyngeal Carriage and Herd Immunity

The most profound public health consequence of the shift to conjugate vaccines lies in their ability to impact disease transmission. N. meningitidis is transmitted from person-to-person via respiratory droplets, and its persistence in a population depends on its ability to colonize the nasopharynx of asymptomatic carriers.[22]

Numerous studies have shown that plain polysaccharide vaccines have a minimal, if any, effect on reducing nasopharyngeal carriage of the meningococcus.[17] They protect the vaccinated individual from invasive disease, primarily by generating antibodies in the blood, but they do not effectively clear the bacteria from the mucosal surfaces of the nose and throat. As a result, a vaccinated individual can still carry and transmit the bacteria to others. This means PSVs are primarily tools for individual protection, not for population-level disease control.

In stark contrast, conjugate vaccines have been demonstrated to reduce the acquisition and density of nasopharyngeal carriage.[16] The proposed mechanism involves the high-avidity IgG antibodies generated by the TD response, which can reach the mucosal surface of the nasopharynx (a process called transudation) and mediate the clearance of colonizing bacteria.[23]

By reducing carriage in vaccinated individuals, conjugate vaccines interrupt the chain of transmission. This confers herd immunity (also known as herd protection), an effect where the vaccination of a sufficiently large proportion of a population (particularly high-carriage groups like adolescents) provides indirect protection to unvaccinated individuals by reducing their overall risk of exposure.[17] This effect dramatically amplifies the public health impact of a vaccination program, representing a fundamental shift in vaccine philosophy from simply protecting the individual to actively managing and controlling disease circulation within the entire community. The inclusion of the serogroup Y antigen in these advanced conjugate vaccines has thus made it an essential component of this powerful public health strategy.

III. The Vaccine Landscape: Formulations Incorporating the Serogroup Y Antigen

The evolution of meningococcal vaccines from simple polysaccharide formulations to complex conjugate and combination products is clearly reflected in the history of vaccines developed to provide protection against serogroup Y. These products vary in their composition, mechanism, and approved indications, charting a clear course of scientific advancement in vaccinology.

3.1. The Legacy Polysaccharide Vaccine: Menomune (MPSV4)

The first quadrivalent meningococcal vaccine to include the serogroup Y antigen was Menomune (MPSV4), a plain polysaccharide vaccine manufactured by Sanofi Pasteur.[24] First licensed by the U.S. Food and Drug Administration (FDA) in 1981, Menomune contained 50 µg each of purified capsular polysaccharide from

N. meningitidis serogroups A, C, Y, and W-135 in each 0.5 mL dose.[7] It was administered via subcutaneous injection.[11]

For decades, Menomune was a key tool for specific high-risk groups, including military recruits, travelers to endemic regions, and individuals with certain immune deficiencies.[24] For many years, it was also the only meningococcal vaccine licensed for use in adults older than 55.[18] However, as the immunological limitations of polysaccharide vaccines—such as short duration of immunity, poor efficacy in infants, and lack of a booster response—became well-understood, its role diminished with the advent of superior conjugate technology. Sanofi Pasteur ultimately discontinued production of Menomune, and the final doses expired in the United States in 2017, officially marking the end of the polysaccharide era for routine meningococcal disease prevention in the country.[18]

3.2. Quadrivalent Conjugate Vaccines (MenACWY): A Comparative Analysis

The development of quadrivalent meningococcal conjugate (MenACWY) vaccines represents the modern standard of care for preventing disease caused by serogroups A, C, W, and Y. These vaccines are all administered as a 0.5 mL intramuscular injection and have become the cornerstone of routine adolescent immunization programs in the U.S. and other countries.[20]

Menactra (MenACWY-D)

• Manufacturer and Composition: Developed by Sanofi Pasteur, Menactra was the first MenACWY conjugate vaccine licensed in the U.S..[18] Each dose contained 4 µg each of the capsular polysaccharides from serogroups A, C, Y, and W-135, individually conjugated to a diphtheria toxoid protein carrier.[2]
• Regulatory History and Status: Menactra was first licensed in 2005 for use in individuals aged 11 to 55 years. Its approval was later expanded to include children as young as 9 months.[22] As a first-generation conjugate vaccine, it played a pivotal role in shifting public health strategy. However, with the development of newer products, Sanofi Pasteur has since discontinued Menactra, and the last available doses expired in 2023.[27]

Menveo (MenACWY-CRM)

• Manufacturer and Composition: Originally developed by Novartis and now part of the GlaxoSmithKline (GSK) portfolio, Menveo utilizes a different formulation.[31] Each dose contains 10 µg of serogroup A oligosaccharide and 5 µg each of serogroups C, Y, and W-135 oligosaccharides. These are conjugated to CRM197, a non-toxic mutant of the diphtheria protein.[20] The vaccine is supplied in two vials—a lyophilized (freeze-dried) MenA component and a liquid MenCYW component—that must be reconstituted prior to administration.[21]
• Regulatory History and Status: Menveo was licensed in the U.S. in 2010. Its approved age range is broad, covering individuals from 2 months through 55 years of age, making it suitable for infant immunization schedules.[18] It remains a widely used MenACWY vaccine.

MenQuadfi (MenACWY-TT)

• Manufacturer and Composition: MenQuadfi is a newer MenACWY conjugate vaccine from Sanofi.[35] It contains 10 µg of polysaccharide from each of the four serogroups (A, C, Y, and W), conjugated to a tetanus toxoid protein carrier.[36] A key practical feature is that it is supplied as a ready-to-use liquid solution, eliminating the need for reconstitution.[38]
• Regulatory History and Status: MenQuadfi was licensed in the U.S. in 2020, initially for individuals aged 2 years and older. Its indication has since been expanded to include infants from 6 weeks of age, positioning it as a direct competitor to Menveo for both infant and adolescent vaccination.[35]

3.3. Next-Generation and Combination Vaccines

The latest evolution in meningococcal vaccine technology aims to provide even broader protection by combining the quadrivalent ACWY components with antigens for serogroup B, the other major cause of meningococcal disease in many regions.

Pentavalent Vaccines (MenABCWY)

These vaccines offer the convenience of protecting against the five most common meningococcal serogroups (A, B, C, W, and Y) in a single product.

• Penbraya (MenACWY-TT/MenB-FHbp): Approved by the FDA in October 2023, Penbraya combines the components of Sanofi's MenQuadfi (MenACWY-TT) and Pfizer's Trumenba (MenB-FHbp). It is approved for individuals aged 10 through 25 years.[18]
• Penmenvy (MenACWY-CRM/MenB-4C): Approved in February 2025, Penmenvy combines components related to GSK's Menveo (MenACWY-CRM) and Bexsero (MenB-4C). It is also approved for the 10- to 25-year-old age group.[18]

Historical Combination Vaccine

A notable past product was MenHibrix, which combined the serogroup C and Y conjugate components with a Haemophilus influenzae type b (Hib) conjugate vaccine. It was licensed for use in infants but was discontinued by GSK in 2017 as the market shifted toward quadrivalent and, eventually, pentavalent formulations.[2]

The following table provides a consolidated overview of these key vaccines, highlighting the central and evolving role of the serogroup Y polysaccharide antigen.

Brand Name	Vaccine Type	Serogroup Y Antigen Dose (µg/0.5 mL)	Carrier Protein	Manufacturer	Initial U.S. Licensure	Current U.S. Approved Age Range	Current Status
Menomune	Polysaccharide (MPSV4)	50	None	Sanofi Pasteur	1981 24	2 years and older	Discontinued (2017) 27
Menactra	Conjugate (MenACWY-D)	4	Diphtheria Toxoid	Sanofi Pasteur	2005 30	9 months - 55 years	Discontinued (2023) 27
Menveo	Conjugate (MenACWY-CRM)	5	Diphtheria CRM197	GSK	2010 33	2 months - 55 years	Available
MenQuadfi	Conjugate (MenACWY-TT)	10	Tetanus Toxoid	Sanofi	2020 35	6 weeks and older	Available
Penbraya	Conjugate (MenABCWY)	5	Tetanus Toxoid	Pfizer	2023 18	10 - 25 years	Available
Penmenvy	Conjugate (MenABCWY)	5	Diphtheria CRM197	GSK	2025 18	10 - 25 years	Available

IV. Clinical Efficacy and Immunogenicity: A Data-Driven Assessment

The clinical superiority of conjugate meningococcal vaccines over their polysaccharide predecessors is not a matter of theory but is substantiated by a robust body of evidence from numerous clinical trials. These studies, which measure the immune response through serological assays—most importantly, the serum bactericidal antibody (SBA) assay—quantitatively demonstrate the enhanced and more durable protection afforded by conjugation technology, particularly for the serogroup Y component.

4.1. Head-to-Head Trials: Polysaccharide (MPSV4) vs. Conjugate (MenACWY) Vaccines

Direct comparative trials have consistently highlighted the superior immunogenicity of MenACWY conjugate vaccines.

• In Older Adults: A study in adults aged 56 to 65 years directly compared the conjugate vaccine MenACWY-CRM (Menveo) with the polysaccharide vaccine MPSV4 (Menomune). One month after vaccination, the geometric mean titers (GMTs) of bactericidal antibodies were 1.2- to 5.4-fold higher in the MenACWY-CRM group than in the MPSV4 group across all four serogroups, including Y.[42]
• In Children: A pivotal study in healthy U.S. children aged 2 to 10 years compared MenACWY-D (Menactra) with MPSV4. The results were definitive: SBA GMTs against all four serogroups were significantly higher in the children who received the conjugate vaccine at both 28 days and 6 months post-vaccination. This finding was instrumental in the Advisory Committee on Immunization Practices (ACIP) preference for the conjugate vaccine in this age group.[32]
• In Vaccine-Naïve Adults: A trial comparing the newer tetanus toxoid conjugate vaccine, MenACWY-TT (MenQuadfi), to MPSV4 in adults aged 56 and older demonstrated that the seroresponse to MenACWY-TT was non-inferior to that of MPSV4 for all four serogroups, establishing its efficacy in an older population for which MPSV4 was once the only option.[43]

While the trend of conjugate superiority is clear, it is important to consider context. A study conducted in Malian children aged 2 to 10 years comparing a quadrivalent polysaccharide vaccine to Menactra found that the immunogenicity profile of the polysaccharide vaccine was non-inferior to the conjugate vaccine at 30 days post-immunization, with similar GMTs and seroconversion rates.[45] This finding does not negate the established long-term advantages of conjugation but suggests that in certain populations, possibly with different background immunity or epidemiological pressures, the short-term immune response to a polysaccharide vaccine can be substantial. This highlights that while conjugate vaccines are immunologically superior for inducing long-term memory and are the standard for routine programs, public health decisions in specific settings, such as short-term outbreak control in resource-limited areas, may involve different considerations.

4.2. Long-Term Antibody Persistence and Booster Response

The most compelling evidence for the paradigm shift from polysaccharide to conjugate vaccines comes from long-term follow-up studies. These trials reveal not just a quantitative difference in antibody levels but a fundamental qualitative difference in the nature of the immune response—the presence or absence of durable immunological memory.

An early comparative study found that three years after vaccination, 76% of subjects who received a conjugate vaccine (MCV-4) still had evidence of passive protection, compared to only 49% of those who received the polysaccharide vaccine (MPSV4).[18] More recent and detailed long-term studies have solidified this conclusion. A landmark phase IIb study conducted in the Philippines and Saudi Arabia followed adolescents and adults (aged 11-55 years) for up to 10 years after they received a single dose of either MenACWY-TT (a conjugate vaccine) or MenACWY-PS (a polysaccharide vaccine).[19]

• At the 5-Year Mark: The data for serogroup Y was striking. Among those who received the MenACWY-TT conjugate vaccine, 90.0% still had protective rabbit SBA (rSBA) titers of ≥1:8. In contrast, this figure was only 74.3% for those who received the MenACWY-PS polysaccharide vaccine. Similarly, 86.3% of the conjugate group maintained higher titers (≥1:128) compared to 68.6% of the polysaccharide group. The GMTs for serogroups A, W, and Y were all significantly higher in the conjugate vaccine group, demonstrating a far more persistent immune response.[46]
• At the 10-Year Mark: The superior persistence of the conjugate vaccine response continued. At 10 years post-vaccination, the percentage of subjects with protective rSBA titers remained generally higher in the MenACWY-TT group compared to the MenACWY-PS group for serogroups A, W, and Y.[47] For serogroup Y specifically, rSBA GMTs in the MenACWY-TT group were substantially higher than in the MenACWY-PS group.[49]
• Booster Response: The 10-year follow-up study also included a booster dose of MenACWY-TT for all participants. The results powerfully demonstrated the effect of immunological memory. One month after the booster, nearly 100% of subjects in both the original conjugate and polysaccharide groups achieved protective antibody titers (rSBA ≥1:8).[48] Crucially, the post-booster GMTs were markedly higher in the group originally primed with the conjugate vaccine, indicating a true, robust anamnestic memory response that is the hallmark of T-cell dependent immunity.[47]

This divergence in long-term protection is a direct clinical manifestation of the immunological principles discussed previously. The sustained antibody levels and potent booster response in the conjugate vaccine groups are the result of T-cell dependent memory, an attribute the T-cell independent polysaccharide vaccines cannot confer. This evidence provides the definitive rationale for the universal recommendation of conjugate vaccines in routine immunization schedules.

4.3. Comparative Immunogenicity Among Conjugate Vaccines

With several MenACWY conjugate vaccines available, studies have also sought to compare their immunogenicity. While all are highly effective, some subtle differences have been observed.

• MenACWY-CRM (Menveo) vs. MenACWY-D (Menactra): In a phase III study involving adults aged 19 to 55, MenACWY-CRM demonstrated a non-inferior immune response to Menactra for all four serogroups. Furthermore, the response to MenACWY-CRM was found to be statistically superior for serogroups C, W, and Y, with post-vaccination GMTs for serogroup Y being consistently higher in the Menveo group.[31]
• MenACWY-TT (MenQuadfi) vs. Other Conjugates: The clinical development program for MenACWY-TT included trials demonstrating its non-inferiority to licensed comparators, including both Menactra and Menveo.[51] A subsequent meta-analysis of available trial data suggested that MenACWY-TT induced a higher immune response for serogroups A, W, and Y when compared to both MenACWY-D and MenACWY-CRM, though the response to serogroup C was comparable.[52]

These findings suggest that while all licensed conjugate vaccines provide robust protection, variations in the carrier protein, antigen dose, and manufacturing process can lead to measurable differences in the magnitude of the immune response to specific serogroups, including serogroup Y.

The following table summarizes key immunogenicity data for serogroup Y from pivotal comparative clinical trials, providing a quantitative basis for these conclusions.

Trial Identifier / Source	Vaccine Comparison	Population	Time Point Post-Vaccination	Serogroup Y Endpoint: % with rSBA ≥ 1:8	Serogroup Y Endpoint: Geometric Mean Titer (GMT)
NCT00162228 / 32	MenACWY-D vs. MPSV4	Children 2-10 yrs	28 Days	Data not specified	Significantly higher for MenACWY-D
NCT00624934 / 42	MenACWY-CRM vs. MPSV4	Adults 56-65 yrs	28 Days	Data not specified	1.2- to 5.4-fold higher for MenACWY-CRM
NCT00453982 / 31	MenACWY-CRM vs. MenACWY-D	Adults 19-55 yrs	28 Days	81% (CRM) vs. 69% (D)	Superior for MenACWY-CRM (GMT Ratio > 1.0)
NCT00356369 / 19	MenACWY-TT vs. MenACWY-PS	Adolescents & Adults 11-55 yrs	5 Years	90.0% (TT) vs. 74.3% (PS)	Higher for MenACWY-TT
NCT01934140 / 47	MenACWY-TT vs. MenACWY-PS	Adolescents & Adults 11-55 yrs	10 Years	69.3-91.2% (TT) vs. 24.4-88.9% (PS)	Higher for MenACWY-TT (146.0–446.9 vs 12.9–191.0)

V. Safety, Tolerability, and Contraindications

The safety profiles of meningococcal vaccines, particularly the modern conjugate formulations, have been extensively studied in large-scale clinical trials and monitored through robust post-marketing surveillance systems. The accumulated evidence overwhelmingly supports a favorable safety profile, which is a critical factor for the successful implementation of routine public health vaccination programs.

5.1. General Safety Profile and Common Adverse Events

The adverse events associated with both polysaccharide and conjugate meningococcal vaccines are generally mild to moderate and transient in nature.[53]

• Menomune (MPSV4): For the legacy polysaccharide vaccine, the most commonly reported adverse events in clinical trials included local injection site reactions such as pain, redness, and induration (hardening of the skin). Systemic reactions included headache, fatigue, malaise (a general feeling of discomfort), and diarrhea.[25]
• MenACWY Conjugate Vaccines: The safety profile of the conjugate vaccines (Menactra, Menveo, and MenQuadfi) is very similar to that of MPSV4 and to each other. The most frequently reported solicited adverse reactions are:
• Local Reactions: Pain at the injection site is the most common local reaction, followed by redness and swelling.[35]
• Systemic Reactions: The most common systemic reactions are headache, myalgia (muscle pain), and fatigue or malaise.[10] In younger children, irritability, drowsiness, and loss of appetite may also be common.[34]

These reactions are typically self-limiting, resolving within one to three days without intervention.53

A known adverse event associated with vaccination in general, particularly among adolescents, is syncope (fainting), which can sometimes result in injury from a fall. For this reason, it is recommended that vaccine recipients, especially adolescents, be seated during administration and observed for approximately 15 minutes afterward.[3]

5.2. Analysis of Serious Adverse Events of Special Interest: Guillain-Barré Syndrome (GBS)

Shortly after the licensure of the first MenACWY conjugate vaccine, Menactra (MenACWY-D), in 2005, reports of Guillain-Barré Syndrome (GBS) occurring in temporal association with vaccination were submitted to the Vaccine Adverse Event Reporting System (VAERS).[22] GBS is a rare neurological disorder in which the body's immune system damages nerve cells, causing muscle weakness and sometimes paralysis. These initial reports prompted a thorough and transparent investigation by public health authorities to determine if a causal link existed.

This process serves as an excellent case study in the functioning of modern pharmacovigilance. The initial signal detected through passive surveillance (VAERS) triggered active, rigorous scientific investigation. Several large-scale epidemiological studies were conducted to assess the risk.[54] The findings from this extensive body of research were consistent:

• The risk of GBS following Menactra vaccination, if it exists at all, is exceedingly small. The attributable risk was estimated to be no more than one potential excess case per million vaccinations.[55]
• Further analyses concluded that the observed rate of GBS among vaccinated individuals was not significantly higher than the expected background rate of GBS that occurs in the general population, regardless of vaccination.[22]

Based on this comprehensive evidence, the ACIP has updated its guidance. A personal history of GBS is no longer considered a formal contraindication or precaution to meningococcal vaccination.[54] The decision to administer a MenACWY vaccine to an individual with a history of GBS is now a matter of clinical judgment, weighing the established benefits of vaccination against the theoretical and very low potential risk.[38] This evolution in guidance reflects a data-driven process that is fundamental to maintaining scientific integrity and public trust in immunization programs.

5.3. Contraindications and Special Populations

Clear guidelines exist for the appropriate use of meningococcal vaccines, including defined contraindications and considerations for special populations.

• Contraindications: The primary and absolute contraindication for any meningococcal vaccine is a history of a severe, life-threatening allergic reaction (e.g., anaphylaxis) to a previous dose of that vaccine or to any of its components.[10] For vaccines that use tetanus toxoid as a carrier protein, such as MenQuadfi and Penbraya, a history of a severe allergic reaction to another tetanus toxoid-containing vaccine is also a contraindication.[35] The vial stoppers for some vaccine presentations may contain dry natural latex rubber, which could cause allergic reactions in latex-sensitive individuals.[25]
• Precautions: Vaccination should generally be deferred for individuals who are moderately or severely ill with an acute condition. This is a general precaution for all vaccinations to avoid confusing symptoms of the illness with potential adverse effects of the vaccine.[10]
• Pregnancy and Lactation: Meningococcal vaccines are not routinely recommended for pregnant or lactating women. However, no specific safety concerns have been identified from the limited available data. Therefore, for a woman who is at increased risk for invasive meningococcal disease, the benefits of vaccination are considered to outweigh the potential risks, and MenACWY conjugate vaccines should be administered if indicated. For MenB vaccines, vaccination should generally be deferred unless the individual is at high risk and the decision is made in consultation with a healthcare provider.[3]
• Altered Immunocompetence: Individuals with compromised immune systems, whether due to conditions like HIV infection or treatments such as chemotherapy or immunosuppressive drugs, may have a diminished immune response to meningococcal vaccines. While vaccination is still recommended for many of these high-risk groups, the level of protection achieved may be lower than in immunocompetent individuals.[20]

VI. Public Health Application and Recommendations

The translation of scientific evidence on vaccine efficacy and safety into effective public health policy is paramount for controlling infectious diseases. In the United States, the Advisory Committee on Immunization Practices (ACIP) provides evidence-based recommendations to the Centers for Disease Control and Prevention (CDC) for the use of vaccines. The current recommendations for meningococcal vaccines containing the serogroup Y antigen are sophisticated and data-driven, targeting populations at the highest risk to maximize both individual and community protection.

6.1. U.S. Advisory Committee on Immunization Practices (ACIP) Recommendations

The cornerstone of the U.S. strategy for preventing meningococcal disease is the routine vaccination of all adolescents with a quadrivalent conjugate (MenACWY) vaccine.[20] This policy is a direct and logical response to clinical data on both disease epidemiology and vaccine immunokinetics.

• Routine Adolescent Schedule: The ACIP recommends a two-dose series for all adolescents:

1. First Dose: Administered at age 11 or 12 years.[10] This dose provides protection as children enter adolescence, a period of increasing social interaction.
2. Booster Dose: Administered at age 16.[10] This booster is critical. The timing is not arbitrary; it is specifically designed to counteract the documented waning of antibody protection that occurs within approximately five years of the initial dose.[36] By boosting immunity at age 16, the schedule ensures that protection is at its peak during the ages of highest risk for meningococcal disease, which are 16 through 23 years.[10]

• Catch-up Vaccination: For adolescents who do not follow the recommended schedule, specific catch-up guidance is provided. If the first dose is administered between ages 13 and 15, a booster dose is still recommended at age 16 through 18. If the first dose is given on or after the 16th birthday, a booster dose is not routinely necessary, as protection is expected to last through the highest-risk years.[27]

It is noteworthy that the universal recommendation for MenACWY vaccination stands in contrast to the recommendation for serogroup B (MenB) vaccines. For healthy adolescents not at increased risk, MenB vaccination is recommended based on a process of shared clinical decision-making between the patient, their parents, and the provider, rather than as a universal requirement.[39] This distinction reflects a complex public health calculus that balances the relative incidence of disease caused by different serogroups, vaccine effectiveness, and the potential for herd immunity. While serogroups C, W, and Y (covered by MenACWY) have caused widespread disease and the conjugate vaccines offer the potential for herd protection, serogroup B disease is comparatively rarer in the U.S., and current MenB vaccines are not believed to significantly impact carriage or confer herd immunity, leading to a more individualized recommendation.[23]

6.2. Vaccination Strategies for High-Risk Populations

Beyond the routine adolescent schedule, the ACIP recommends MenACWY vaccination for children (starting from as young as 2 months, depending on the vaccine product) and adults who have specific conditions that place them at increased risk for invasive meningococcal disease.[10] These high-risk groups include:

• Individuals with Immune Deficiencies: This includes persons with anatomic or functional asplenia (e.g., sickle cell disease), those with persistent complement component deficiencies, and individuals receiving complement inhibitor drugs like eculizumab or ravulizumab.[10]
• Persons with HIV Infection: Vaccination is recommended for individuals living with HIV.[10]
• Individuals with Increased Exposure Risk: This category includes microbiologists who are routinely exposed to isolates of N. meningitidis, U.S. military recruits, and individuals traveling to or residing in regions where meningococcal disease is hyperendemic or epidemic, such as the "meningitis belt" of sub-Saharan Africa.[10]
• Persons at Risk During an Outbreak: Vaccination is recommended for individuals identified as being at increased risk during a community outbreak caused by a vaccine-preventable serogroup.[10]

For individuals with ongoing high-risk conditions, maintaining protective immunity is crucial. Therefore, the ACIP recommends regular booster doses of MenACWY vaccine following the primary series. The interval for these boosters is typically every 5 years for those aged 7 and older, and every 3 years for younger children, to ensure continuous protection throughout the period of risk.[3]

6.3. Administration and Co-administration Guidelines

Proper administration is essential for vaccine effectiveness and safety.

• Route and Site: All currently available MenACWY and MenABCWY vaccines are administered as a 0.5 mL dose via the intramuscular (IM) route.[2] The recommended injection site for adolescents and adults is the deltoid muscle of the upper arm. For infants and young children, the preferred site is the vastus lateralis muscle in the anterolateral thigh.[29]
• Co-administration: Clinical studies have shown that MenACWY vaccines can be safely and effectively administered concomitantly with other vaccines that are routinely recommended for the same age groups, such as the Tetanus, Diphtheria, and Acellular Pertussis (Tdap) vaccine and the Human Papillomavirus (HPV) vaccine.[29] When multiple vaccines are given during the same visit, they should be administered using separate syringes and at different anatomical sites, if feasible.[29]
• Combination Products: If an individual is eligible and indicated for both MenACWY and MenB vaccination at the same visit, a pentavalent MenABCWY vaccine (e.g., Penbraya, Penmenvy) may be used as a convenient alternative to two separate injections.[29]

VII. Synthesis and Concluding Remarks

7.1. The Evolving Role of the Serogroup Y Antigen in Meningococcal Prophylaxis

The scientific and clinical journey of the meningococcal serogroup Y polysaccharide antigen (DB13888) encapsulates the remarkable progress in modern vaccinology over the past four decades. Initially identified as the key virulence factor of an increasingly significant strain of Neisseria meningitidis, its first application in a vaccine was as a component of the quadrivalent plain polysaccharide vaccine, Menomune. This first-generation technology, while a crucial step forward, was constrained by the fundamental nature of its T-cell independent immune response, which resulted in short-lived protection, poor efficacy in infants, and an inability to generate immunological memory.

The transformative breakthrough came with the advent of conjugation technology. By covalently linking the serogroup Y polysaccharide to a protein carrier, scientists successfully converted it into a T-cell dependent antigen. This unlocked a cascade of immunological benefits that define the current standard of care: the induction of high-avidity, class-switched IgG antibodies; the generation of long-term immunological memory capable of mounting a potent booster response; and high immunogenicity even in the youngest and most vulnerable infants.

Perhaps most importantly from a public health perspective, this technological leap endowed vaccines with the ability to reduce nasopharyngeal carriage of the bacterium, thereby interrupting transmission and conferring herd immunity—a feat unattainable with the older polysaccharide vaccines. The serogroup Y antigen is now an indispensable component of the highly effective and durable quadrivalent (MenACWY) and pentavalent (MenABCWY) conjugate vaccines that form the backbone of meningococcal disease prevention strategies in the United States and many other parts of the world. Its evolution from a component in a limited-use vaccine to a cornerstone of routine immunization programs is a testament to how a deep understanding of immunology, driven by epidemiological need, can lead to the development of powerful tools for protecting human health.

7.2. Future Directions and Unanswered Questions

Despite the tremendous success of current meningococcal conjugate vaccines, several areas warrant continued research and policy evaluation to further optimize disease prevention.

• Duration of Immunity and Booster Strategies: While 10-year persistence data for conjugate vaccines is strong, questions remain regarding the ultimate duration of protection and the necessity of booster doses beyond the currently recommended adolescent schedule. Further long-term follow-up is needed to determine if and when adults vaccinated as adolescents might require additional boosters, particularly as they age and their immune systems change.[64] The optimal booster intervals for individuals with ongoing high-risk conditions also merit continued study.
• Real-World Effectiveness and Impact of New Vaccines: The newest quadrivalent (MenQuadfi) and pentavalent (Penbraya, Penmenvy) vaccines have demonstrated excellent immunogenicity in clinical trials. However, continued post-marketing surveillance is essential to confirm their real-world effectiveness in diverse populations and to fully assess their long-term impact on disease incidence, bacterial carriage, and herd immunity.[60]
• Integration of Pentavalent Vaccines: The availability of MenABCWY vaccines presents a new option for adolescent vaccination. The key questions for public health bodies will be how to best integrate these products into existing schedules, their cost-effectiveness compared to separate MenACWY and MenB administration, and their impact on vaccine uptake and completion rates.
• Global Health Equity: The advanced and relatively expensive conjugate vaccines that are standard in high-income countries are not universally accessible. Addressing the challenge of making these life-saving technologies affordable and available in lower-resource settings, where the burden of meningococcal disease can be immense, remains a critical priority for global health. Understanding the potential role of different vaccine technologies, including potentially lower-cost polysaccharide or novel conjugate formulations, in specific epidemiological contexts will be vital to achieving equitable protection worldwide.[45]

Works cited

1. Neisseria meningitidis - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Neisseria_meningitidis
2. Meningococcal polysaccharide vaccine group Y - DrugBank, accessed July 28, 2025, https://go.drugbank.com/drugs/DB13888
3. Meningococcal - Institute for Vaccine Safety, accessed July 28, 2025, https://www.vaccinesafety.edu/meningococcal/
4. Impact and effectiveness of meningococcal vaccines: a review - SciELO - Saúde Pública, accessed July 28, 2025, https://www.scielosp.org/article/rpsp/2017.v41/e158/
5. Meningococcal ACWY Vaccines - MenACWY and MPSV4: What You Need to Know Information | Mount Sinai - New York, accessed July 28, 2025, https://www.mountsinai.org/health-library/special-topic/meningococcal-acwy-vaccines-menacwy-and-mpsv4-what-you-need-to-know
6. Impact and effectiveness of meningococcal vaccines: a review - PMC - PubMed Central, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6660876/
7. Prevention of Meningococcal Disease: Current Use of Polysaccharide and Conjugate Vaccines - Oxford Academic, accessed July 28, 2025, https://academic.oup.com/cid/article/50/Supplement_2/S45/343284
8. Description and Nomenclature of Neisseria meningitidis Capsule Locus - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3647402/
9. Chemical structure of meningococcal capsular polysaccharide repeating... - ResearchGate, accessed July 28, 2025, https://www.researchgate.net/figure/Chemical-structure-of-meningococcal-capsular-polysaccharide-repeating-units-from_fig1_351120862
10. Meningococcal ACWY Vaccine VIS | Vaccines & Immunizations | CDC, accessed July 28, 2025, https://www.cdc.gov/vaccines/hcp/current-vis/meningococcal-acwy.html
11. Meningococcal Polysaccharide Vaccine, Groups A, C, Y, W135 Combined (Menomune) - Amazon S3, accessed July 28, 2025, https://s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13889.pdf?1505428542
12. Meningococcal polysaccharide Group Y Vaccine - Therapeutic Proteins, accessed July 28, 2025, https://therapeutic.creativebiomart.net/meningococcal-polysaccharide-group-y-vaccine.html
13. Structural determination of the polysaccharide antigens of Neisseria meningitidis serogroups Y, W-135, and BO - Canadian Science Publishing, accessed July 28, 2025, https://cdnsciencepub.com/doi/10.1139/o76-001
14. (a) Structures of meningococcal polysaccharides. (b) Space-filling... | Download Scientific Diagram - ResearchGate, accessed July 28, 2025, https://www.researchgate.net/figure/a-Structures-of-meningococcal-polysaccharides-b-Space-filling-model-of-Neisseria_fig1_6035151
15. Structure of meningococcal polysaccharides A and C. - ResearchGate, accessed July 28, 2025, https://www.researchgate.net/figure/Structure-of-meningococcal-polysaccharides-A-and-C_fig1_307968222
16. Conjugate and Polysaccharide Vaccines - Neisseria.org, accessed July 28, 2025, https://neisseria.org/ipnc/1996/Neis1996-chap4.pdf
17. Meningococcal conjugate vaccines: optimizing global impact - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3215346/
18. Meningococcal vaccine - Wikipedia, accessed July 28, 2025, https://en.wikipedia.org/wiki/Meningococcal_vaccine
19. Long-term immunogenicity and safety after a single dose of the quadrivalent meningococcal serogroups A, C, W, and Y tetanus toxoid conjugate vaccine in adolescents and adults: 5-year follow-up of an open, randomized trial - Bohrium, accessed July 28, 2025, https://www.bohrium.com/paper-details/long-term-immunogenicity-and-safety-after-a-single-dose-of-the-quadrivalent-meningococcal-serogroups-a-c-w-and-y-tetanus-toxoid-conjugate-vaccine-in-adolescents-and-adults-5-year-follow-up-of-an-open-randomized-trial/814592030561796098-9179
20. Meningococcal Groups A, C, Y, and W-135 Vaccine monograph - Drugs.com, accessed July 28, 2025, https://www.drugs.com/monograph/meningococcal-groups-a-c-y-and-w-135-vaccine.html
21. Package Insert - MENVEO - FDA, accessed July 28, 2025, https://www.fda.gov/media/78514/download
22. Meningococcal Vaccine (MPSV4, MCV4): Schedule and Side Effects - WebMD, accessed July 28, 2025, https://www.webmd.com/children/vaccines/meningococcal-vaccine
23. Herd Protection against Meningococcal Disease through ..., accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7693901/
24. History of Meningococcal Vaccine - National Vaccine Information ..., accessed July 28, 2025, https://www.nvic.org/disease-vaccine/meningitis/vaccine-history
25. Menomune: Package Insert / Prescribing Information - Drugs.com, accessed July 28, 2025, https://www.drugs.com/pro/menomune.html
26. Past, present, and future policy considerations regarding meningococcal vaccination in the United States, accessed July 28, 2025, https://www.tandfonline.com/doi/full/10.1080/14760584.2024.2397705
27. Ask the Experts: Meningococcal ACWY: Vaccine Recommendations - Immunize.org, accessed July 28, 2025, https://www.immunize.org/ask-experts/topic/menacwy/vaccine-recommendations-menacwy/
28. Meningococcal Vaccines - Medical Clinical Policy Bulletins - Aetna, accessed July 28, 2025, https://www.aetna.com/cpb/medical/data/300_399/0356.html
29. Meningococcal Vaccine Administration - CDC, accessed July 28, 2025, https://www.cdc.gov/vaccines/vpd/mening/hcp/administering-vaccine.html
30. Menactra (meningococcal conjugate vaccine) FDA Approval History - Drugs.com, accessed July 28, 2025, https://www.drugs.com/history/menactra.html
31. Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra | Clinical and Vaccine Immunology - ASM Journals, accessed July 28, 2025, https://journals.asm.org/doi/10.1128/cvi.00207-09
32. Notice to Readers: Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Use of Quadrivalent Meningococcal Conjugate Vaccine (MCV4) in Children Aged 2 - CDC, accessed July 28, 2025, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5648a4.htm
33. MENVEO | FDA, accessed July 28, 2025, https://www.fda.gov/vaccines-blood-biologics/vaccines/menveo
34. Package Insert - MENVEO - FDA, accessed July 28, 2025, https://www.fda.gov/files/bioinformatics%20tools/published/Package-Insert---Menveo.pdf
35. MenQuadfi (meningococcal (groups A, C, Y, W) conjugate vaccine) FDA Approval History, accessed July 28, 2025, https://www.drugs.com/history/menquadfi.html
36. About Meningococcal Vaccines - CDC, accessed July 28, 2025, https://www.cdc.gov/vaccines/vpd/mening/hcp/about-vaccine.html
37. Package Insert and Information for Patients - MenQuadfi - FDA, accessed July 28, 2025, https://www.fda.gov/media/137306/download
38. Meningococcal Meningitis (MenACWY) Vaccine | MenQuadfi® (Meningococcal [Groups A, C, Y, W] Conjugate Vaccine), accessed July 28, 2025, https://www.menquadfi.com/
39. Meningococcal Vaccine Recommendations - CDC, accessed July 28, 2025, https://www.cdc.gov/meningococcal/hcp/vaccine-recommendations/index.html
40. A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT) - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12153384/
41. Meningococcal Disease Vaccine - AAFP, accessed July 28, 2025, https://www.aafp.org/family-physician/patient-care/prevention-wellness/immunizations-vaccines/disease-pop-immunization/meningococcal-disease-vaccine.html
42. Safety and immunogenicity of an investigational quadrivalent ..., accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/20655261/
43. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9980625/
44. Study Details | Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older | ClinicalTrials.gov, accessed July 28, 2025, https://clinicaltrials.gov/study/NCT02842866
45. (PDF) Safety and immunogenicity of quadrivalent meningococcal ..., accessed July 28, 2025, https://www.researchgate.net/publication/372108122_Safety_and_immunogenicity_of_quadrivalent_meningococcal_polysaccharide_vaccine_MPV_ACYW135_compared_with_quadrivalent_meningococcal_conjugate_vaccine_MenactraR_in_Malian_children
46. Long-term immunogenicity and safety after a single dose of the ..., accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/26437712/
47. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safety of a booster dose in individuals aged 11 through 55 years - PubMed, accessed July 28, 2025, https://pubmed.ncbi.nlm.nih.gov/32552685/
48. A phase 2b/3b MenACWY-TT study of long-term antibody persistence after primary vaccination and immunogenicity and safet… - OUCI, accessed July 28, 2025, https://ouci.dntb.gov.ua/en/works/9j8m6vq4/
49. 4. MenACWY-TT Long-Term Antibody Persistence Following Adolescent Vaccination and Evaluation of a Booster Dose: A Review of Clinical Data - ResearchGate, accessed July 28, 2025, https://www.researchgate.net/publication/348172388_4_MenACWY-TT_Long-Term_Antibody_Persistence_Following_Adolescent_Vaccination_and_Evaluation_of_a_Booster_Dose_A_Review_of_Clinical_Data
50. Efficacy and safety of a booster dose of the meningococcal A, C, W, Y-tetanus toxoid conjugate vaccine administered 10 years after primary vaccination and long-term persistence of tetanus toxoid conjugate or polysaccharide vaccine, accessed July 28, 2025, https://www.tandfonline.com/doi/full/10.1080/21645515.2020.1744363
51. Evidence to Recommendations for MenACWY-TT (MenQuadfi) Meningococcal Vaccine | ACIP | CDC, accessed July 28, 2025, https://www.cdc.gov/acip/evidence-to-recommendations/mening-MenACWY-TT-EtR.html
52. Efficacy and Safety of Quadrivalent Conjugate Meningococcal Vaccines: A Systematic Review and Meta-Analysis - MDPI, accessed July 28, 2025, https://www.mdpi.com/2076-393X/11/1/178
53. Meningococcal Vaccination - CDC, accessed July 28, 2025, https://www.cdc.gov/meningococcal/vaccines/index.html
54. Meningococcal Vaccine Safety - CDC, accessed July 28, 2025, https://www.cdc.gov/vaccine-safety/vaccines/meningococcal.html
55. Current safety issues with quadrivalent meningococcal conjugate vaccines - PMC, accessed July 28, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5989904/
56. Safety Profile | MENVEO [Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM₁₉₇ Conjugate Vaccine], accessed July 28, 2025, https://www.menveohcp.com/safety/
57. Meningococcal-vaccine - Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Hepatic Dose | Drug Index | Pediatric Oncall, accessed July 28, 2025, https://www.pediatriconcall.com/drugs/meningococcal-vaccine/743
58. Meningococcal polysaccharide vaccine, diphtheria conjugate (intramuscular route) - Side effects & uses - Mayo Clinic, accessed July 28, 2025, https://www.mayoclinic.org/drugs-supplements/meningococcal-polysaccharide-vaccine-diphtheria-conjugate-intramuscular-route/description/drg-20075376
59. Meningococcal Vaccine - Infectious Diseases - MSD Manual ..., accessed July 28, 2025, https://www.msdmanuals.com/professional/infectious-diseases/immunization/meningococcal-vaccine
60. Types of Meningococcal Vaccines - CDC, accessed July 28, 2025, https://www.cdc.gov/meningococcal/vaccines/types.html
61. CDC Recommendations | TRUMENBA® (Meningococcal Group B Vaccine) | Safety Info, accessed July 28, 2025, https://trumenba.pfizerpro.com/about/cdc-recommendations
62. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020 | MMWR - CDC, accessed July 28, 2025, https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm
63. Meningococcal disease - The Australian Immunisation Handbook, accessed July 28, 2025, https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/meningococcal-disease
64. Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine - Bohrium, accessed July 28, 2025, https://www.bohrium.com/paper-details/antibody-persistence-up-to-5-years-after-vaccination-of-toddlers-and-children-between-12-months-and-10-years-of-age-with-a-quadrivalent-meningococcal-acwy-tetanus-toxoid-conjugate-vaccine/814580952255692801-10397
65. Different Long-Term Duration of Seroprotection against Neisseria meningitidis in Adolescents and Middle-Aged Adults after a Single Meningococcal ACWY Conjugate Vaccination in The Netherlands - MDPI, accessed July 28, 2025, https://www.mdpi.com/2076-393X/8/4/624